SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody weapon targets brain lymphoma in early trial
Disease control OngoingThis study tests a new drug called GNC-038 in people with a type of brain lymphoma that has returned or not responded to treatment. The main goals are to check the drug's safety and find the best dose. About 7 adults will take part, and researchers will also look for early signs …
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 05:45 UTC
-
New cocktail targets Hard-to-Treat brain lymphoma
Disease control OngoingThis study tests a combination of six drugs (TEDDI-R) for people whose aggressive B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this mix can control the cancer better than current treatments. About 48 adults will take the drugs in 21-day cycles for…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 12:07 UTC